Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00144365
Other study ID # CDC-NCHSTP-4371
Secondary ID 1U01PS000065-01
Status Completed
Phase Phase 3
First received September 2, 2005
Last updated September 10, 2012
Start date February 2005
Est. completion date December 2010

Study information

Verified date September 2012
Source Centers for Disease Control and Prevention
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Interventional

Clinical Trial Summary

The study is a 3-year, randomized trial to compare ART delivery through two different models: a) ART delivered through health facilities by clinically qualified staff and b) home-based care in which lay workers, i.e. non-medically qualified people, play a major role in the ART delivery and clients are followed up at health facilities less frequently. The primary objective is to measure the effects of these strategies on HIV viral load. We will also examine the effects on treatment failure, disease progression, survival, adherence, family member HIV testing, sexual behavior, and cost-effectiveness.


Description:

The study is a randomized trial to compare ART delivery through two different models: a) ART delivered through health facilities by clinically qualified staff and b) home-based care in which lay workers, i.e. non-medically qualified people, play a major role in the ART delivery and clients are followed up at health facilities less frequently. The primary objective is to measure the effects of these strategies on plasma HIV viral load. We will also examine the effects on treatment failure, disease progression, survival, adherence, family member HIV testing, sexual behavior, and cost-effectiveness.

The trial is conducted with The AIDS Support Organization (TASO) clinic in Jinja, Uganda. Randomization is conducted through geographic clusters, defined using sub-counties in the district, and stratified by distance from fixed health facilities, and urban/rural. Just over 800 participants, living in 40 clusters, will be recruited over a period of 3-6 months and followed-up over a period of 3 years.


Recruitment information / eligibility

Status Completed
Enrollment 1453
Est. completion date December 2010
Est. primary completion date December 2008
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

HIV infection Plan to remain resident in the area for at least 12 months CD4 cell count <200 cells/mm3 or severe symptomatic HIV (WHO stage 3 or 4) Identify a medicine companion who will assist in adherence to ART treatment Age 18 years or above.

Exclusion Criteria:

Abnormal liver and renal function test results (AST or ALT = 5x upper limit of normal Calculated creatinine clearance < 25 ml/min). The tests are conducted only in individuals in whom they are clinically indicated

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label


Related Conditions & MeSH terms


Intervention

Drug:
Antiretroviral therapy


Locations

Country Name City State
Uganda The AIDS Support Organization Jinja

Sponsors (3)

Lead Sponsor Collaborator
Centers for Disease Control and Prevention British Medical Research Council, The AIDS Support Organization

Country where clinical trial is conducted

Uganda, 

Outcome

Type Measure Description Time frame Safety issue
Primary HIV viral load
Secondary Medication adherence
Secondary Treatment failure
Secondary Morbidity
Secondary Survival
Secondary Sexual behavior
Secondary Family member HIV testing
Secondary cost-effectiveness
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06044792 - The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in PLWH
Not yet recruiting NCT03661203 - Investigation of the Psychosocial Factors Responsible for the Late Recourse to HIV Testing Within MSM
Completed NCT02711878 - Healing Hearts and Mending Minds in Older Adults Living With HIV N/A
Completed NCT02606344 - Effect of a Micro-finance-based Intervention for the Prevention of Intimate-partner Violence and HIV N/A
Completed NCT01053598 - Evaluation Of The Performance Of The Nitrate Reductase And Resazurin Titre Assay For The Detection of Mycobacterium Tuberculosis Complex From Sputum In A High Tb and Hiv Setting N/A
Completed NCT01348308 - Immuno-stimulation With Maraviroc Combined to Antiretroviral Therapy in Advanced Late Diagnosed HIV-1 Infected Patients Phase 3
Completed NCT01237366 - Study Targeting Affect Regulation Phase 1/Phase 2
Withdrawn NCT00951795 - Accuracy of the Pima™ CD4 Test for Enumeration of CD4+ T-Cell Counts N/A
Completed NCT00740389 - TMC125-TiDP2-C187: A Phase I, Open-label Trial to Investigate the Pharmacokinetic Interaction Between TMC125 and Two Antifungal Agents (Fluconazole and Voriconazole), All at Steady-state in Healthy Subjects. Phase 1
Withdrawn NCT00347750 - Pharmacokinetics and Pharmacodynamics of an Anti-HIV Drug in Israeli Ethiopian and Non-Ethiopian Populations Phase 3
Withdrawn NCT00340223 - HLA-B35 Alleles and AIDS N/A
Completed NCT00317460 - Buprenorphine and Integrated HIV Care Phase 4
Completed NCT00144352 - In-Vivo Response of P. Falciparum to Antimalarial Treatment in HIV-Infected and HIV-Uninfected Adults Phase 4
Completed NCT01084395 - Reducing HIV Risk Among Mexican Youth N/A
Completed NCT00202241 - The Effects of Anabolic Steroids and Protease Inhibitors on People Living With HIV/AIDS N/A
Completed NCT00341172 - The Effects of Genetic Differences Among AIDS Patients on Cytomegalovirus Retinitis
Recruiting NCT06145841 - Metagenomic Next-Generation Sequencing Guides Anti-Infection Strategies
Completed NCT03633721 - Acute Effects of Cannabis on Cognition and Mobility in Older HIV-infected and HIV-Un-infected Women Phase 2
Completed NCT04567693 - Reducing Time to Spaced-out Appointments for Newly-diagnosed People Living With HIV N/A
Completed NCT03023033 - Supporting Attendance for Facility Delivery and Infant Health N/A